Sitaxentan

• N-(4 -chloro-3 -methylisoxazole -5-yl ) -2 - [ (4,5- methylenedioxy- 2-methylphenyl) acetyl] thiophene-3 -sulfonamide
• Latin: Sitaxentanum

C02KX03

Antihypertensives

Endothelin receptor antagonist

Template: Infobox chemical / molecular formula search available

Thelin (trade name: Thelin ®, Manufacturer: Encysive, a subsidiary of Pfizer Group ), is an endothelin receptor antagonist and was as an alternative to ambrisentan and bosentan as so-called orphan drug for the treatment of rare lung high blood pressure ( pulmonary hypertension, NYHA class III) allowed.

Pharmacology

Has been demonstrated in clinical studies that Thelin improves physical performance in patients with pulmonary hypertension and slow the progression of the disease symptoms. Simultaneously, the blood flow to the lungs improved by enlargement of the pulmonary arteries.

Other Information

In Germany Thelin was in December 2006 on the market and has been sold in the form of tablets. The daily treatment costs amounted to about 117 €. Patients taking the drug (1 tablet daily ) must be measured on a monthly basis their liver values ​​since the substance class of endothelin receptor antagonists may impair liver function. After two associated with taking the drug deaths due to liver failure, the preparation was taken in December 2010 in Germany from the market.